Mirabegron

Articles · Medicine Compliance Aid Stability · Lactation Safety Information · New Medicines ·

703804000

Articles

Drugs for urinary disorders – are any lactose-free?

This Medicine Q&A gives details of available urinary frequency, enuresis, incontinence and urinary retention preparations that do not contain lactose. There is a lactose-free preparation… Alfuzosin Bethanechol Darifenacin Desmopressin Doxazosin Duloxetine Dutasteride Finasteride Imipramine Lactose Mirabegron Oxybutynin Prazosin Propiverine Q&A Renal and urologic disorders Solifenacin Solifenacin + Tamsulosin Tamsulosin Tamsulosin + Dutasteride Tolterodine Trospium

Medicine Compliance Aid Stability

Betmiga · Astellas Pharma Ltd

Astellas Pharma Ltd
Betmiga
Tablets m/r 25mg, 50mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from moisture
Protect from moisture in an airtight container.
21st September 2015

Lactation Safety Information

Oxybutynin
Long half-life increases risk of accumulation in breastfed infants
No published evidence of safety

New Medicines

Betmiga (EU) Myrbetriq (US) · Neurogenic detrusor overactivity in children

Information

Betmiga (EU) Myrbetriq (US)
Licence extension / variation
Astellas
Astellas

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

Beta 3 receptor agonist
The incidence of the problem is reported as 8.4% in girls and 1.7% in boys [3].
Neurogenic detrusor overactivity in children
Oral